Loading clinical trials...
Loading clinical trials...
To Conduct a Phase IV Clinical Trial of Recombinant Mycobacterium Tuberculosis Fusion Protein in Community Population Aged 6 Months and Above.
Conditions
Interventions
Recombinant Mycobacterium tuberculosis fusion protein for injection
TB-PPD was injected
Locations
1
China
Guangxi Zhuang Autonomous Region Center for Disease Control and Prevention
Liuchow, Guangxi, China
Start Date
April 17, 2023
Primary Completion Date
May 13, 2024
Completion Date
May 13, 2024
Last Updated
September 19, 2024
NCT06033807
NCT00804713
NCT02225158
NCT00558480
NCT01875952
NCT00463086
Lead Sponsor
Anhui Zhifei Longcom Biologic Pharmacy Co., Ltd.
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions